BioCentury
ARTICLE | Clinical News

Tysabri natalizumab: Interim postmarketing study data

May 7, 2012 7:00 AM UTC

Interim data from the prospective, U.S. STRATIFY-2 trial in >35,000 patients receiving Tysabri showed that the incidence of progressive multifocal leukoencephalopathy (PML) was significantly lower in patients who tested negative for anti-JCV antibodies vs. anti-JCV antibody positive patients (p=0.0004). At baseline, the overall prevalence of anti-JCV antibodies was 53.5%, which Biogen Idec said is consistent with other clinical research in MS patients. Data were presented at the American Academy of Neurology meeting in New Orleans. ...